Efficacy and Safety of AQX-1125 in Unstable COPD

Summary

The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src Homology 2-containing Inositol-5'-Phosphatase 1) pathway.

Timeline

Start

2013-10

Primary completion

2015-07

Completion

2015-12

Outcome

Missed primary endpoint

registry analysis (superiority or other test); AQX-1125 (200mg) vs Placebo; p = 0.759; Least sqaure mean difference 23.7 (95% CI -128.3 to 175.7); ANOVA; NCT01954628 ↗

Drugs

Indications